Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICROGESTIN 1/20 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing estrogen (ethinyl estradiol) and progestin (norethindrone acetate). Inhibits gonadotropin secretion (FSH, LH) via negative feedback, preventing ovulation. Also causes cervical mucus thickening and endometrial thinning.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females ≥15 years who have achieved menarche and are using oral contraception (FDA approved for this indication with 20 mcg ethinyl estradiol formulation)
Prevention of pregnancy (FDA-approved)
One tablet (norethindrone acetate 1 mg / ethinyl estradiol 20 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethindrone: 5.2-12.8 hours (mean ~8 hours); Ethinyl estradiol: 7-20 hours (mean ~13 hours); hepatic impairment prolongs.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol metabolized primarily by CYP3A4 via hydroxylation; also conjugated with sulfate and glucuronic acid. Norethindrone acetate deacetylated to norethindrone, then metabolized by reduction and conjugation; CYP3A4 minor role.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: 40% as metabolites, 20% as glucuronide and sulfate conjugates; Fecal: 35%; Biliary: <5%.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: 60-80% bound to SHBG and albumin; Ethinyl estradiol: 95-98% bound to albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: 3.4-5.5 L/kg; Ethinyl estradiol: 2.6-4.4 L/kg; reflects extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: Norethindrone 64-70%; Ethinyl estradiol 38-48% (first-pass metabolism).
Oral: ~70% due to first-pass metabolism.
No specific dose adjustment recommended; data limited. Use caution in patients with significant renal impairment due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in severe hepatic disease (Child-Pugh C) due to impaired steroid metabolism. Use lowest effective dose in mild to moderate impairment (Child-Pugh A/B) with close monitoring.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) with monitoring for adverse effects.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use after menopause due to increased risk of thromboembolic events and cardiovascular complications.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events (e.g., myocardial infarction, stroke, thromboembolism) from COC use. Risk increases with age (especially >35) and number of cigarettes smoked. Women >35 who smoke should not use COCs.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Risk of thromboembolic disorders (e.g., DVT, PE, stroke, MI) - discontinue if symptoms occur,Increased risk of myocardial infarction, especially in smokers ≥35,Elevated blood pressure - monitor periodic BP,Gallbladder disease risk,Hepatic neoplasia risk (benign/malignant) - discontinue if jaundice develops,May worsen diabetes, hyperlipidemia, or migraines,Women with history of depression should be monitored,Retinal thrombosis - discontinue if visual symptoms occur,Increased risk of pancreatitis in women with hypertriglyceridemia,Possible increase in breast cancer risk - individual risk/benefit assessment
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Hepatic adenoma or carcinoma (current or history),Jaundice or liver disease with impaired function (active),Hypersensitivity to any component,Age >35 and smokes
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food restrictions; however, grapefruit juice may increase estrogen levels and is best avoided. High-fat meals may delay absorption but not clinically significant.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Microgestin 1/20 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester exposure has been associated with a small increase in risk of congenital anomalies, including cardiovascular and limb defects. Use in second and third trimesters may cause fetal harm, including female pseudohermaphroditism with high doses of progestins.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Small amounts of contraceptive steroids have been identified in breast milk, with an estimated M/P ratio of approximately 0.3 for ethinyl estradiol. Norethindrone acetate is also excreted. Use may reduce milk production and composition, especially with early postpartum use. Generally not recommended during breastfeeding due to potential effects on the infant.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Microgestin 1/20 is contraindicated in pregnancy and should be discontinued immediately if pregnancy is suspected. No dose adjustments are applicable as the drug is not used during pregnancy. Physiological changes in pregnancy may affect pharmacokinetics, but no established dosing recommendations exist due to contraindication.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Initiate on first day of menstrual period or first Sunday after onset; no need for back-up contraception if started within first 5 days. Missed pill protocols: if 1 pill missed, take as soon as remembered; if 2+ pills missed, take last missed pill, use back-up for 7 days. May reduce menstrual cramps and acne. Contraindicated in smokers over 35 and those with history of DVT or migraine with aura.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time to maintain steady hormone levels.,If you miss a pill, refer to the package insert for instructions; use backup contraception if needed.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, which usually improve after 2-3 cycles.,This medication does not protect against HIV or other STDs; use condoms for protection.,Notify your provider if you experience severe abdominal pain, chest pain, shortness of breath, or vision changes.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICROGESTIN 1/20 vs AFIRMELLE, answered by our medical review team.
MICROGESTIN 1/20 is a Oral Contraceptive that works by Combination oral contraceptive containing estrogen (ethinyl estradiol) and progestin (norethindrone acetate). Inhibits gonadotropin secretion (FSH, LH) via negative feedback, preventing ovulation. Also causes cervical mucus thickening and endometrial thinning.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICROGESTIN 1/20 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICROGESTIN 1/20 is: One tablet (norethindrone acetate 1 mg / ethinyl estradiol 20 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICROGESTIN 1/20 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICROGESTIN 1/20 is classified as Category C. Microgestin 1/20 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester exposure has been associated with a small increase in risk of congenital. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.